In:
European Journal of Haematology, Wiley, Vol. 93, No. 3 ( 2014-09), p. 229-238
Abstract:
The increasing number of longer living patients with follicular lymphoma ( FL ) and serious side effects of treatment urged us to study the health‐related quality of life ( HRQ o L ) and persistent (treatment‐related) symptoms in unselected patients after different treatment modalities and compare HRQ o L of patients with a normative population. Methods The population‐based E indhoven Cancer Registry was used to select patients diagnosed with FL during 2004–2010. The E uropean O rganisation for R esearch and T reatment of C ancer Q uality of L ife Q uestionnaire C ore 30 ( EORTC QLQ ‐ C 30) was completed twice, with a 1‐yr interval. This questionnaire was also completed by an age‐ and sex‐matched normative population ( N = 580). Detailed data on treatment were extracted from the cancer registry and Population‐based HA ematological R egistry for O bservational S tudies ( PHAROS ). Results Of the 181 patients who were invited, 148 responded (82%, T 1). Patients treated with immunochemotherapy reported clinically relevant higher mean fatigue scores than those who underwent radiotherapy ( P = 0.02). No differences were observed on the other HRQ o L scales between treatment groups. Mean HRQ o L scores were worse for FL patients treated with immunochemotherapy compared with a normative population ( P 〈 0.01). A quarter to 50% of patients persistently reported to be slowed down, lethargic, or persistently worried about future health or was limited in social activities. Subsequently, patients reporting these symptoms/worries had a lower global health status/ HRQ o L . Conclusion Alertness for persistent symptoms that occur during and after treatment of FL patients is needed and may help to avoid lasting negative influence on their HRQ o L .
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2014.93.issue-3
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2027114-1
Permalink